An in silico study of new 1-aminoquinoline-2(1H)-one derivatives as tyrosine kinase inhibitors

The field of oncology has been revolutionized by the discovery and development of targeted therapies for cancer. A study focuses on the development of tyrosine kinase inhibitors (TKIs) as effective targeted therapies. Although TKIs have shown promise in targeting cancer cell signaling pathways, the emergence of resistance poses a significant challenge, necessitating the development of novel and potent inhibitors. Virtual docking simulations, which use molecular docking algorithms and scoring functions, predict how these TKIs bind to the enzyme and assess their binding strength. Preliminary results show that several of the designed TKIs have a strong binding affinity and form key interactions with the target tyrosine kinase. These interactions include hydrogen bonds, hydrophobic interactions, and electrostatic interactions, which are crucial for stabilizing the complex between the TKI and the enzyme. Additionally, the study identifies specific amino acid residues within the tyrosine kinase binding site that enhance the binding affinity of the TKIs. This detailed information is valuable for further optimizing TKI design and developing more effective inhibitors with improved binding properties.